These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

657 related items for PubMed ID: 16777491

  • 1. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients.
    Panunti B, Fonseca V.
    Vascul Pharmacol; 2006 Jul; 45(1):29-35. PubMed ID: 16777491
    [Abstract] [Full Text] [Related]

  • 2. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM, Schiffrin EL.
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [Abstract] [Full Text] [Related]

  • 3. Can PPARgamma agonists have a role in the management of obesity-related hypertension?
    Chetty VT, Sharma AM.
    Vascul Pharmacol; 2006 Jul; 45(1):46-53. PubMed ID: 16713364
    [Abstract] [Full Text] [Related]

  • 4. Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice.
    Verreth W, De Keyzer D, Pelat M, Verhamme P, Ganame J, Bielicki JK, Mertens A, Quarck R, Benhabilès N, Marguerie G, Mackness B, Mackness M, Ninio E, Herregods MC, Balligand JL, Holvoet P.
    Circulation; 2004 Nov 16; 110(20):3259-69. PubMed ID: 15533870
    [Abstract] [Full Text] [Related]

  • 5. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists.
    Libby P, Plutzky J.
    Am J Cardiol; 2007 Feb 19; 99(4A):27B-40B. PubMed ID: 17307056
    [Abstract] [Full Text] [Related]

  • 6. Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance.
    Guo L, Tabrizchi R.
    Pharmacol Ther; 2006 Jul 19; 111(1):145-73. PubMed ID: 16305809
    [Abstract] [Full Text] [Related]

  • 7. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.
    Duan SZ, Usher MG, Mortensen RM.
    Circ Res; 2008 Feb 15; 102(3):283-94. PubMed ID: 18276926
    [Abstract] [Full Text] [Related]

  • 8. Modulation of cardiac and aortic peroxisome proliferator-activated receptor-gamma expression by oxidative stress in chronically glucose-fed rats.
    El Midaoui A, Wu L, Wang R, de Champlain J.
    Am J Hypertens; 2006 Apr 15; 19(4):407-12. PubMed ID: 16580578
    [Abstract] [Full Text] [Related]

  • 9. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Wilding JP.
    Diabetes Obes Metab; 2012 Nov 15; 14(11):973-82. PubMed ID: 22443197
    [Abstract] [Full Text] [Related]

  • 10. PPAR-gamma receptor agonists--a review of their role in diabetic management in Trinidad and Tobago.
    Smith SI.
    Mol Cell Biochem; 2004 Aug 15; 263(1-2):189-210. PubMed ID: 15524180
    [Abstract] [Full Text] [Related]

  • 11. Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?
    Feinstein DL, Spagnolo A, Akar C, Weinberg G, Murphy P, Gavrilyuk V, Dello Russo C.
    Biochem Pharmacol; 2005 Jul 15; 70(2):177-88. PubMed ID: 15925327
    [Abstract] [Full Text] [Related]

  • 12. Dual PPAR alpha/gamma agonists: promises and pitfalls in type 2 diabetes.
    Ahmed I, Furlong K, Flood J, Treat VP, Goldstein BJ.
    Am J Ther; 2007 Jul 15; 14(1):49-62. PubMed ID: 17303976
    [Abstract] [Full Text] [Related]

  • 13. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes.
    Blaschke F, Caglayan E, Hsueh WA.
    Endocrinol Metab Clin North Am; 2006 Sep 15; 35(3):561-74, ix. PubMed ID: 16959586
    [Abstract] [Full Text] [Related]

  • 14. Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect.
    Sarafidis PA, Lasaridis AN.
    Am J Hypertens; 2006 Jun 15; 19(6):646-53. PubMed ID: 16733240
    [Abstract] [Full Text] [Related]

  • 15. Therapeutical effects of PPAR agonists assessed by biomarker modulation.
    Chinetti-Gbaguidi G, Fruchart JC, Staels B.
    Biomarkers; 2005 Nov 15; 10 Suppl 1():S30-6. PubMed ID: 16298909
    [Abstract] [Full Text] [Related]

  • 16. Evolution of peroxisome proliferator-activated receptor agonists.
    Chang F, Jaber LA, Berlie HD, O'Connell MB.
    Ann Pharmacother; 2007 Jun 15; 41(6):973-83. PubMed ID: 17519293
    [Abstract] [Full Text] [Related]

  • 17. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.
    Gross B, Staels B.
    Best Pract Res Clin Endocrinol Metab; 2007 Dec 15; 21(4):687-710. PubMed ID: 18054742
    [Abstract] [Full Text] [Related]

  • 18. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
    Cavender MA, Lincoff AM.
    Am J Cardiovasc Drugs; 2010 Dec 15; 10(4):209-16. PubMed ID: 20653327
    [Abstract] [Full Text] [Related]

  • 19. The complex role of PPARgamma in renal dysfunction in obesity: managing a Janus-faced receptor.
    Dobrian AD.
    Vascul Pharmacol; 2006 Jul 15; 45(1):36-45. PubMed ID: 16716756
    [Abstract] [Full Text] [Related]

  • 20. The effect of PPARgamma ligands on the adipose tissue in insulin resistance.
    Hammarstedt A, Andersson CX, Rotter Sopasakis V, Smith U.
    Prostaglandins Leukot Essent Fatty Acids; 2005 Jul 15; 73(1):65-75. PubMed ID: 15936183
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.